Latest Options News

Vintage Energy has launched a $2.1 million equity entitlement offer to fund drilling two new gas wells, supported by a South Australian government grant, and to advance oil exploration in the Cooper Basin.

Sequoia Financial Group faces a pivotal shift as HUB24 stops accepting new business from its InterPrac Financial Planning advisers, prompting a strategic transition for the company’s adviser network.

Key Petroleum Ltd has completed a modest 3% share placement but will not proceed with the remaining 13%, leaving questions over its funding strategy.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

TMK Energy has raised $6 million in a heavily oversubscribed placement led by coal seam gas experts, aiming to accelerate drilling and commercialisation at its Gurvantes XXXV project.

Novo Resources has officially listed over 25 million free-attaching options on the ASX, following its recent capital raising. These options, exercisable at 15 cents, underpin the company’s ongoing exploration ambitions across Western Australia and New South Wales.

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.

Caspin Resources has successfully completed a $6 million placement and exercised options, bolstering its position in promising Australian mineral projects focused on tin and gold.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

MLG Oz Limited has locked in a 24-month contract extension at Northern Star’s Jundee Gold Mine, promising steady revenue and continued operational support.

Chimeric Therapeutics Limited has announced a significant 100-to-1 security consolidation affecting shares, options, and performance rights, pending shareholder approval and set for implementation in April 2026.

GR Engineering Services Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.12 per share and setting the Dividend Reinvestment Plan price at AUD 3.9507 with a 2.5% discount.